Spironolactone
(Synonyms: 螺内酯; SC9420) 目录号 : GC12516
Spironolactone是一种具有口服活性的盐皮质激素受体（MR；IC50=24nM）和雄激素受体（AR；IC50=77nM）双重拮抗剂。
Cas No.:52-01-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Spironolactone is an orally active dual antagonist of the mineralocorticoid receptor (MR; IC₅₀=24nM) and androgen receptor (AR; IC₅₀=77nM)[1-2]. Spironolactone exerts potassium-sparing diuretic effects by antagonizing aldosterone and modulates hormone-related diseases through Spironolactone anti-androgenic activity. Spironolactone is applicable in research areas such as heart failure, cancer, hypertension, and female acne and androgenetic alopecia[3-4].
In vitro, pretreatment of MC3T3-E1 osteoblasts with Spironolactone (0.01–1μM) for 1 hour, followed by stimulation with Methylglyoxal (400μM) for 48 hours, Spironolactone significantly inhibited Methylglyoxal-induced cell death and apoptosis, and improved bone formation activity. Spironolactone reduced Methylglyoxal-induced endoplasmic reticulum stress, intracellular reactive oxygen species generation, mitochondrial superoxide levels, and cardiolipin peroxidation, while also suppressing the secretion of inflammatory cytokines[5]. Treatment of H295R adrenocortical cells with Spironolactone (0.1–30μM) for 24 hours, Spironolactone significantly inhibited basal cortisol and aldosterone production. Spironolactone inhibits the activity of steroidogenic enzymes[6].
In vivo, intraperitoneal administration of Spironolactone (50mg/kg body weight/day) to tumor-bearing (CSCL or SLGC cells) NOD-SCID mice (starting from day 21 post-cell inoculation, twice a week for three weeks), Spironolactone significantly inhibited tumor growth and reduced the proportion of cancer stem cells within the tumor, while inducing apoptosis in cancer cells and cancer stem cells by impairing the DNA damage response[7]. Oral gavage administration of Spironolactone (50mg/kg body weight/day) to BALB/c mice with experimental autoimmune myocarditis (starting from day 7 post-immunization, once daily for four weeks), Spironolactone significantly improved myocardial hypertrophy and diastolic function, reduced inflammatory cytokine levels, and decreased collagen deposition and myocardial fibrosis by inhibiting the TGF-β1/Smad-2/3/Ets-1 signaling pathway[8].
References:
[1] Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008 Apr;31(4):153-8.
[2] Karim A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8(1):151-88.
[3] Ershadi S, Barbieri JS. Spironolactone for Acne: Practical Strategies for Optimal Clinical Outcomes. Cutis. 2025 Jul;116(1):26-31.
[4] Heymann WR. Spironolactone and breast cancer: Fear not! J Am Acad Dermatol. 2020 Oct;83(4):1008-1009.
[5] Park SY, Suh KS, Jung WW, et al. Spironolactone Attenuates Methylglyoxal-induced Cellular Dysfunction in MC3T3-E1 Osteoblastic Cells. J Korean Med Sci. 2021 Oct 4;36(38):e265.
[6] Ye P, Yamashita T, Pollock DM, et al. Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis. Horm Metab Res. 2009 Jan;41(1):35-9.
[7] Gold A, Eini L, Nissim-Rafinia M, et al. Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. Oncogene. 2019 Apr;38(17):3103-3118.
[8] Wang WK, Wang B, Cao XH, et al. Spironolactone alleviates myocardial fibrosis via inhibition of Ets-1 in mice with experimental autoimmune myocarditis. Exp Ther Med. 2022 Jun;23(6):369.
Spironolactone是一种具有口服活性的盐皮质激素受体（MR；IC50=24nM）和雄激素受体（AR；IC50=77nM）双重拮抗剂[1-2]。Spironolactone通过拮抗醛固酮发挥保钾利尿作用，并凭借抗雄激素活性调节激素相关疾病，Spironolactone可用于心力衰竭、癌症、高血压以及女性痤疮和雄激素源性脱发等相关研究[3-4]。
在体外，Spironolactone（0.01–1μM）预处理MC3T3-E1成骨细胞1小时，随后使用甲基乙二醛（400μM）刺激细胞48小时，Spironolactone显著抑制甲基乙二醛诱导的细胞死亡和凋亡，并改善骨形成活性。Spironolactone降低甲基乙二醛诱导的内质网应激、细胞内活性氧生成、线粒体超氧化物水平和心磷脂过氧化，同时抑制炎症因子的分泌[5]。Spironolactone（0.1–30μM）处理H295R肾上腺皮质细胞24小时，Spironolactone显著抑制基础皮质醇和醛固酮的产生。Spironolactone抑制类固醇生成酶的活性[6]。
在体内，Spironolactone（50mg/kg体重/天）腹腔注射处理荷瘤（CSCL或SLGC细胞）NOD-SCID小鼠（从接种细胞后第21天开始，每周两次，持续三周），Spironolactone显著抑制肿瘤生长并降低肿瘤内癌症干细胞比例，同时通过损害DNA损伤反应诱导癌细胞和癌症干细胞凋亡[7]。Spironolactone（50mg/kg体重/天）灌胃处理实验性自身免疫性心肌炎BALB/c小鼠（从免疫后第7天开始，每天一次，持续四周），Spironolactone显著改善心肌肥厚和舒张功能，降低炎症因子水平，并通过抑制TGF-β1/Smad-2/3/Ets-1信号通路减少胶原沉积和心肌纤维化[8]。
| Cell experiment [1]: | |
Cell lines | MC3T3-E1 cells (mouse osteoblastic cell line) |
Preparation Method | MC3T3-E1 cells were cultured in α-minimal essential medium (α-MEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were pretreated with Spironolactone (0.01–1μM) for 1 hour, followed by co-treatment with Methylglyoxal (MG; 400μM) for 48 hours. |
Reaction Conditions | 0.01–1μM; 48 hours. |
Applications | Spironolactone significantly prevented MG-induced cytotoxicity and apoptosis in MC3T3-E1 cells. Spironolactone restored osteoblast differentiation markers, including collagen synthesis, alkaline phosphatase (ALP) activity, and mineralization. Spironolactone reduced MG-induced endoplasmic reticulum stress, intracellular reactive oxygen species (ROS), mitochondrial superoxide production, and cardiolipin peroxidation. |
| Animal experiment [2]: | |
Animal models | NOD-SCID mice (for tumor growth assessment) and BALB/c mice (for EAM model) |
Preparation Method | Mice were injected with transformed cells to generate tumors. After 3 weeks of tumor development, Spironolactone (50mg/kg) was administered intraperitoneally twice weekly for three consecutive weeks. |
Dosage form | 50mg/kg; i.p.; twice weekly for three consecutive weeks. |
Applications | Spironolactone significantly inhibited tumor growth and reduced cancer stem cell (CSC) content in NOD-SCID mice. |
References: | |
| Cas No. | 52-01-7 | SDF | |
| 别名 | 螺内酯; SC9420 | ||
| 化学名 | S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate | ||
| Canonical SMILES | CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C | ||
| 分子式 | C24H32O4S | 分子量 | 416.57 |
| 溶解度 | ≥ 18mg/mL in DMSO | 储存条件 | Store at RT,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4006 mL | 12.0028 mL | 24.0056 mL |
| 5 mM | 480.1 μL | 2.4006 mL | 4.8011 mL |
| 10 mM | 240.1 μL | 1.2003 mL | 2.4006 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet